Your browser version may not work well with NCBI's Web applications. More information here...
1: Oncogene. 2006 Mar 13;25(11):1620-8.
Related Articles, Links
Click here to read
Cyclin D1: polymorphism, aberrant splicing and cancer risk.

Knudsen KE, Diehl JA, Haiman CA, Knudsen ES.

Department of Cell Biology, University of Cincinnati, Cincinnati, OH 45267, USA. erik.knudsen@uc.edu

The cyclin D1 proto-oncogene exercises powerful control over the mechanisms that regulate the mitotic cell cycle, and excessive cyclin D1 expression and/or activity is common in human cancers. Although somatic mutations of the cyclin D1 locus are rarely observed, mounting evidence demonstrates that a specific polymorphism of cyclin D1 (G/A870) and a protein product of a potentially related alternate splicing event (cyclin D1b) may influence cancer risk and outcome. Herein, we review the epidemiological and functional literatures that link these alterations of cyclin D1 to human tumor development and progression.

Publication Types:
PMID: 16550162 [PubMed - indexed for MEDLINE]